IGNT-News Out

[mickymoose99]

IGNT
Up 20% at the close Friday
Last Trade @ .0006 On the support
Culd possible test or push thru the next resistance @ .0007
Charts are showing positive signs
RSI 43.53 Uptrend
Mad D pulled away from the signal
ULT @ 28.98 Buyers Market
Click here to Watch a Video Chart of IGNT

Ingen Technologies Forges an Indelible Mark In the Medical World With Projected Revenues of $200 Million in the Oxygen Cannula Market

"Featured Report"

For More Information about INGEN TECHNOLOGIES, INC. Visit their Web Site @

[Chuck.W]

IGNT had another great volume day yesterday going over 96 million. Last trade was @ 0.0005 where it has very stong support and has been bouncing off of regularly for the past month. There is no substantial resistance till the 50day MA. @ 0.00092. I think we could see IGNT make a big move coming off this support. Time to take a position at this excellent entry point. IMO. Good luck to all.

[stocksamongus]

$IGNT no where to go but up here See if you can get in here @ .0004 if you can and be patient. The most recent news break for $IGNT made us see an increase in activity, leading to volume spikes

[RAZOR11]

another great day on this one today.Lots of chatter about news hittin the wire. Good time to take a position in this one

[stocksalot]

in the nine months ended February 28, 2010, $100,000 of cash sales and a $100,000 pending
purchase order were from one customer, Medox Corporation, with whom we have entered into other
transactions, including sales of Series A preferred stock and restricted common stock to both Medox and
its President, Jeffrey Gleckman. We had also previously issued to Medox convertible debentures on June
1, 2004 for $225,000, March 15, 2007 for $200,000, September 1, 2008 for $225,000 and September 1,
2009 for $300,000 in consideration for services rendered to the Company in assisting with its sales and
marketing of Oxyview

[gucci88]

.Ingen Technologies Forges an Indelible Mark In the Medical World With Projected Revenues of $200 Million in the Oxygen Cannula Market

Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0004 0.0000


{"s" : "ignt.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Friday June 4, 2010, 8:15 am EDT

YUCAIPA, Calif., June 4, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) the leading global medical device manufacturer of intelligent oxygen nasal cannulas focused on the $4 billion respiratory market, today announced that its innovative SMART Nasal Cannula with Oxyview technology are addressing unmet needs with an expected $200 million in revenues over the next 5 years.



Ingen has recently noticed a nice spike in sales from respiratory equipment manufacturers who require Ingen's gas flow meter technology for their own medical equipment.



Since 2007 when Ingen first introduced Oxyview to the world of COPD patients, the acceptance of the product has been impressive. There is no other product like Oxyview that provides the additional information that patients and clinicians rely upon. With approximately 23 million patients in the U.S. -- and an estimated 600 million patients worldwide -- who suffer from chronic obstructive pulmonary disease (COPD), Ingen stands to capture $200M in revenues over the next 5 years. Since an average COPD patient uses two to three nasal cannulas each month to prevent bacteria build-up within the device, creating a growing recurring demand for the cannula is an additional benefit to Ingen's bottom line.



View Fact Sheet:



Ingen's SMART Nasal Cannula is superior and very different than that of the conventional oxygen nasal cannulas on the market that now are commoditized products and mass produced overseas and offer patients very little peace-of-mind. As a result, it is not uncommon for home care providers to make frequent visits to oxygen patients concerned that oxygen is not flowing from the tank to the cannula, since there is no way to accurately verify it.



Ingen's one-of-a-kind, patented, high quality SMART Nasal Cannula solves this problem by confirming the flow of oxygen and proper equipment function at roughly the same cost as a traditional cannula. The result is lower costs for home care providers and greater peace-of-mind for in-home oxygen patients with respiratory diseases like COPD.



"Ingen's innovative oxygen cannulas are rapidly gaining traction due to their unique ability to lower costs for home care providers and provide peace-of-mind for oxygen patients," said Ingen CEO Scott Sand. "We have already booked more than $160,000 in revenues during the fourth quarter with $300,000 more in OEM orders backlogged, in addition to $1.4M in government contracts -- and we're just scratching the surface."

[fordf250]

Company Update From the Chairman of Ingen Technologies
Gold Standard Set in Respiratory Market With Promising Fourth Quarter Results


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0004 0.0000


{"s" : "ignt.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Friday June 11, 2010, 5:15 pm EDT

YUCAIPA, Calif., June 11, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, today announced the following information updating shareholders on company progress:



During Ingen's fourth quarter the company focused aggressively on its marketing and advertising saturation campaign. This included being a featured product at the Las Vegas MedTrade Spring conference. The company has also published full color advertisements in major medical publications, such as COPD Digest, AARC Times, Everything Respiratory, LUNG Magazine, Today's Senior Magazine, and many others. Management is focused and dedicated to branding the company's product lines and increasing sales and distribution. Ingen is also scheduled for several major market conferences during the first quarter-2010, including Alpha-1 in Orlando, MedTrade in Georgia and AARC.



During the fourth quarter Ingen filed two more provisional patents; one for its new IngenThermo drug product, and the other for its new cannula technology. The IngenThermo uses polymer-crystal technology to keep insulin and other glass vile drugs cool and safe. Ingen's engineering team is working on the tooling and molds to manufacture this new product using medical-grade polycarbonate as an insulating material, along with polymer-crystals. We expect to deliver this product during the first quarter-2010. The new cannula technology involves the use of special materials that are embedded within the PVC of the nasal cannula. As oxygen flows, it will change the color of the cannula which would indicate a specific flow rate. This technology will complement Ingen's Oxyview technology and secure the company's position as maintaining the gold-standard within the respiratory oxygen therapy market.



The fourth quarter ended May 31, 2010 has proven to drive Ingen in the right direction with increased sales, increased assets and a decrease in debts. Specifically, sales were 80% higher in the fourth quarter as compared to the third quarter. Total sales for fourth quarter were approximately $10,000, as compared to $5,576 ending in the third quarter. The company was able to decrease the $4.5M note to its major note holders to $1.9M. It is expected that the company will fully reduce the balance of the notes over the first quarter of 2010. The company has a pending purchase order from a major distributor for $100,000 expected to ship in July with new inventory. Another expected purchase order from one of our OEM partners amounts to $120,000. Further, the company's government services consultant is expected to close $1.4M in government sales during the first and second quarters of 2010, while GSA evaluates the company's application submitted in September 2009. GSA usually takes 6-12 months to complete and approve applications. The company expects to reach its projected sales of $11M by end of our 2010 fiscal year. BSI (UK) is evaluating Ingen's CE Mark application, and we expect to achieve the CE Mark during our first quarter of 2010. The CE Mark and the ISO 13485:2003 certification allows the company to fulfill export orders for China, Canada, Australia and the European Communities. The People's Republic of China is also currently evaluating the company's ISO Registration, and it is expected that its products will reach the Chinese market by July 2010.



During our fourth quarter, Ingen secured a signed GPO contract with MediGroup Physician Services; one of the nation's largest GPO for the alternate site marketplace, which consists of specialty physicians and surgery centers. MediGroup provides its customers with the purchasing power that is traditionally reserved for hospitals, while enabling participating manufacturers and distributors to deliver products and services to a focused demographic. A Group Purchasing Organization (GPO) is an entity that helps health care providers - such as hospitals, nursing homes and home health agencies - realize cost-savings and efficiencies by aggregating purchasing volume and using that leverage to negotiate discounts with manufacturers, distributors and other vendors. There are more than 600 organizations in the United States that participate in some form of group purchasing. The company is negotiating several other GPO contracts to grow its sales in the hospital commercial market, and expects to see revenues from MediGroup during the first quarter-2010.



Ingen is at its reflex point and on the verge of tremendous growth, after enduring a number of regulatory and economic obstacles. In the face of economic headwinds, the company obtained both FDA and ISO Certification and launched several new and inspiring medical products in the respiratory market. As a result of this success, we have attracted many investors and new shareholders. The company's product line is essentially recession-proof and continues to gain momentum in the respiratory markets. Ingen has made important changes to foster a growth culture with a clear vision for the future. With these successes and changes, the company has undergone a restructuring in order to align their incentives with that of their shareholders. The company is now keenly focused on growth, open communication, and leadership by example, as it works diligently to expand its sales and deliver shareholder value.



Ingen has developed a global perspective on the markets in which it competes. First, the company conducted a thorough market study for our products with InTouch Life Science Corporation, while at the same time filing patents and trademarks for our proprietary technology; second, the company properly registered their products with the FDA and qualified the products for FDA export; third, the company hired Emergo Group, a recognized global consulting firm that assisted us with the ISO 13485 Certification, CE Mark and distribution partners in order to comply with the world markets for distribution of their medical products; and finally, the company hired KGMA Business Solutions, a leading consulting firm to prepare and file their GSA Contract, as well as develop government contracts with the VA Hospitals and Department of Defense. More important, Ingen has lowered their production costs for their products, increased their margins and the margins of their distributors, while keeping a competitive edge on pricing their products in today's challenging medical markets.



"I continue to believe that our inspiration comes from many sources - our shareholders, customers and consumers, as well as our critics. Our staff and consulting team have a passion for what they do that ignites this inspiration every day, everywhere we do business. We remain fresh, relevant and original by knowing what to change without changing what we know. We are asking more questions, listening more closely, and collaborating more effectively with our distribution partners and strategic consultants to give our customers the product they need, and provide our shareholders with the results that they deserve and expect," said Ingen CEO Scott Sand.












Ingen Technologies specializes in marketing, developing and distributing of medical technology products. Products designed by Ingen are providing effective and reliable solutions to medical professionals and patients worldwide while also enabling companies like Lincare Holdings (LNCR) and Cardinal Health, Inc. (CAH) the ability to meet a low cost minimization point which could help save the industry billions of dollars and improve patient quality of life -- a value proposition that is impossible to ignore for very long!

[RAZOR11]

IGNTs news. This is some big news for the company. I am expecting some record high volume in the am with some real nice gains. This is an awesome time to load up on this one before it explodes in the am. Stock has been trading with some great volume the past few days trading days with no news at all. If you have been watchin this one like I suggested you would have noticed theres a few shorts on this one but Imo there is no way in hell there holdin this one back in the am. I also think were going to have a great week. Im thinkn ten bagger, but that is just my excited opinion.

[stocksalot]

Ingen Technologies, Inc. (IGNT), Manufacturer of the New SMART Nasal Cannula for the Home Care Provider Market and Hospital Market, is Featured Side-by-Side Mid and Large Cap Companies Such as Baxter (BAX) at the Alpha-1 19th Annual National Education Conference



YUCAIPA, Calif., June 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.



The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.



"We were very pleased to be an exhibitor and sponsor at this year's conference for Alpha-1. There are hundreds of patient members of the Alpha-1 Association, and many of them attended the conference, along with clinicians and physicians from around the globe. Our new SMART Nasal Cannula was featured and well accepted by the attendees. It is our goal to pick up the pace in supporting the various associations that support patients who require home oxygen therapy and the use of our products," stated Scott R. Sand, CEO and Chairman of the Board.

[GreenGiant]

Ingen Unveils the New SMART Nasal Cannula at Alpha-1
Ingen at the Alpha-1 Association National Conference in Orlando, Florida


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0004 0.0000


{"s" : "ignt.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Monday June 14, 2010, 8:15 am

Ingen Technologies, Inc. (IGNT), Manufacturer of the New SMART Nasal Cannula for the Home Care Provider Market and Hospital Market, is Featured Side-by-Side Mid and Large Cap Companies Such as Baxter (BAX) at the Alpha-1 19th Annual National Education Conference



YUCAIPA, Calif., June 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.



The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.



"We were very pleased to be an exhibitor and sponsor at this year's conference for Alpha-1. There are hundreds of patient members of the Alpha-1 Association, and many of them attended the conference, along with clinicians and physicians from around the globe. Our new SMART Nasal Cannula was featured and well accepted by the attendees. It is our goal to pick up the pace in supporting the various associations that support patients who require home oxygen therapy and the use of our products," stated Scott R. Sand, CEO and Chairman of the Board.

[RAZOR11]

News out on this one again this morning. Awesome volume coming in on this one today. I expect to see alot more from the company this week and weeks to come. Were at a great entry point here. There is rumors of the company announcing contracts after the bell. Hope to see that one hit the wire soon. Good luck to you all

[Chuck.W]

IGNT closed yesterday +25.00% on huge volume over 305 million. RSI is showing an upward trend with the signal line pulling away from the Mac D. Last trade @ 0.0004. Should be another strong day for IGNT.

[stocksalot]

Press Release Source: Ingen Technologies, Inc. On Friday June 18, 2010, 5:00 pm EDT

YUCAIPA, Calif., June 18, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line for the $8B respiratory market, announced today that the company has officially accepted to be an exhibitor and sponsor at the upcoming Medtrade conference in Atlanta, Georgia from November 15-18, 2010 at the Georgia World Congress Center.



The Home Medical Equipment industry is constantly evolving, but one thing remains the same -- the demand for the latest products and technology will be at Medtrade where thousands of qualified attendees will be there to buy the products and services that are right for their customers, and that will ensure the success of their business. Ingen will introduce the new IngenThermo drug product, as well as their Oxyview product line and SMART Nasal Cannula.



The company plans to seize this great opportunity to take advantage of all Medtrade has to offer. The company will showcase its products and services, and create new alliances.



"We are focused on product sales and marketing. Our tradeshow attendance will double this year in order to brand our products. We look forward to a very successful and prosperous fiscal year 2010," stated Scott R. Sand, CEO and Chairman of the Board.

[mickymoose99]

Ingen Scheduled for Medtrade-Atlanta
Management and Consulting Partners Pushing Hard to Meet $11M Projected Sales


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0004 +0.0001


{"s" : "ignt.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Friday June 18, 2010, 5:00 pm EDT

YUCAIPA, Calif., June 18, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line for the $8B respiratory market, announced today that the company has officially accepted to be an exhibitor and sponsor at the upcoming Medtrade conference in Atlanta, Georgia from November 15-18, 2010 at the Georgia World Congress Center.



The Home Medical Equipment industry is constantly evolving, but one thing remains the same -- the demand for the latest products and technology will be at Medtrade where thousands of qualified attendees will be there to buy the products and services that are right for their customers, and that will ensure the success of their business. Ingen will introduce the new IngenThermo drug product, as well as their Oxyview product line and SMART Nasal Cannula.



The company plans to seize this great opportunity to take advantage of all Medtrade has to offer. The company will showcase its products and services, and create new alliances.



"We are focused on product sales and marketing. Our tradeshow attendance will double this year in order to brand our products. We look forward to a very successful and prosperous fiscal year 2010," stated Scott R. Sand, CEO and Chairman of the Board.
















About Ingen:



Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

[stocksamongus]

Ingen Will Attend AARC and AzSRC to Exhibit New Products
Management Expands Marketing Tradeshow Programs


.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Tuesday June 29, 2010, 8:00 am EDT

YUCAIPA, Calif., June 29, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line targeting the $8B respiratory market, announced today that the company has expanded its tradeshow schedule to include the Arizona Society for Respiratory Care (AzSRC) 44th Annual Conference in August 2010 and the American Association for Respiratory Care (AARC) 56th International Respiratory Conference in December 2010.



The AzSRC conference, which will be held in Phoenix, Arizona, is sponsored by the Arizona Society for Respiratory Care (AzSRC), a non-profit organization that supports and benefits the Respiratory Care Practitioners of Arizona. AzSRC, a chartered affiliate of the American Association for Respiratory Care, was founded to enhance communications and the distribution of information among its members and those interested in Respiratory Care.



The 56th International Respiratory Conference for AARC, which will be held in Las Vegas, Nevada by the American Association for Respiratory Care (AARC) is committed to enhancing the professionalism for respiratory care practitioners, improving their performance on the job, and helping them broaden the scope of knowledge essential to their success. Founded in 1949 with more than 49,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.



"We continue to reach out to key end markets in order to accelerate our growth in the medical marketplace," said Chairman and CEO Scott R. Sand. "Our intellectual property and proprietary medical products are rapidly gaining recognition in the world markets, while our products continue to see strong domestic demand as well."

[Chuck.W]

Ingen Debuts Medical Products to U.S. Army

KGMA Business Solutions Tradeshow Line-Up



Press Release Source: Ingen Technologies, Inc. On Wednesday July 7, 2010, 8:00 am EDT

YUCAIPA, Calif., July 7, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a medical device manufacturer with an emerging new medical product line targeting the $8B respiratory market, announced today that the company's strategic government contract consultant, KGMA Business Solutions, has scheduled two major tradeshows for August and September, 2010.


Ingen will debut its new Smart Nasal Cannula on August 10-11, 2010 at the 13th Annual Force Health Protection Conference (FHP) in Phoenix, Arizona; and again on September 8th, 2010 at the Fort Detrick Vendor Day in Frederick, Maryland.


The FHP Conference provides a venue to educate attendees about health promotion, disease and injury prevention, health risks from occupational and environmental health threats and zoonotic diseases, and related preventive medicine and public health topics in garrison and deployed settings. This event will include representatives from DoD, VA and other U.S. Government agencies, academia, industry partners, and allied nations.


Fort Detrick Vendor Day will host the Defense Medical Materiel Program Office (DMMPO), U.S. Army Medical Materiel Agency (USAMMA), the Naval Medical Logistics Command (NAVMEDLOGCOM), the Air Force Medical Evaluation Support Activity (AFMESA), the Air Force Medical Logistics Office (AFMLO), and the U.S. Marine Corp Systems Command. The focus of this year's venue is on "new" products.


"KGMA Business Solutions has structured an aggressive tradeshow schedule while they work at closing $1.4M in government purchases," said Chairman and CEO Scott R. Sand. "Our marketing program is targeted for $11M in the 2010 fiscal year sales."


13th Annual Force Health Protection Conference | Exclusively at Events In America


Vendor Day Announcement, Fort Detrick


Ingen Tech


SMART NASAL CANNULA with Oxyview Technology - Home - Yucaipa, CA 92399, CA


Pulse Oximeter - Home - Yucaipa, CA 92399, CA


About Ingen:


Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.


The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.